E1-INT (Transition Therapeutics/Novo Nordisk).
Transition Therapeutics (through its acquisition of Waratah Pharmaceuticals), in collaboration with Novo Nordisk, is developing E1-INT, an injectable islet neogenesis therapy comprising an epidermal growth factor analog and a gastrin analog, for the treatment of insulin-dependent (type 1) and non-insulin-dependent (type 2) diabetes. The compound is currently undergoing phase II clinical trials.
von Herrath
Matthias
M
La Jolla Institute for Allergy and Immunology, Department of Developmental Immunology, San Diego, CA 92121, USA. matthias@liai.org
D000818:Animals; D002986:Clinical Trials as Topic; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D004345:Drug Industry; D004815:Epidermal Growth Factor / Q000819:agonists / Q000737:chemistry / Q000627:therapeutic use*; D005755:Gastrins / Q000819:agonists / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000737:chemistry / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
C506657:E1-INT; D005755:Gastrins; D007004:Hypoglycemic Agents; D004815:Epidermal Growth Factor